Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

InspireMD announces next generation MGuard Prime net protective Cobalt Chromium stent system

InspireMD, Ltd. announced today the next generation MGuard stent, MGuard Prime(R), a net protective Cobalt Chromium stent system. MGuard Prime(R) offers an advanced patented Cobalt Chromium design, superior flexibility and excellent deliverability on top of the established benefits of the MGuard MicroNet(R) technology.

26 May 2010

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.

26 May 2010

Research findings on pediatric ILD published online in PED

An insightful and in-depth presentation of the most up-to-date clinical and research findings and historical perspectives on pediatric interstitial lung disease is presented in a special issue published online ahead of print in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc.

26 May 2010

PIONEER trial evaluates new safe concept of stent-drug combination

Blue Medical today announced a major step forward in its quest to improve the quality of life of patients with cardiovascular disease, with the start of the PIONEER trial, in which a new safe concept of stent-drug combination is evaluated.

26 May 2010

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Trigemina, Inc., a Mountain View based privately-held biopharmaceutical company, reports positive results from a time-based interim analysis of its Phase IIa clinical trial in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston. The study compares intranasal oxytocin with placebo in patients suffering from CDH.

26 May 2010

Joint research by UB and CDC could lead to new generation of antiviral medicines

Future pandemics of seasonal flu, H1N1 and other drug-resistant viruses may be thwarted by a potent, immune-boosting payload that is effectively delivered to cells by gold nanorods, report scientists at the University at Buffalo and the U.S. Centers for Disease Control and Prevention. The work is published in the current issue of the Proceedings of the National Academy of Sciences.

25 May 2010

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Researchers testing a vaginal microbicide based on a new type of anti-HIV drug found it provided monkeys significant protection against infection with a virus similar to HIV, according to a study reported at the International Microbicides Conference in Pittsburgh today.

24 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

Elixir Medical announces presentations from EXCELLA II Clinical Trial at 2010 EuroPCR

Elixir Medical Corporation, a developer of innovative drug eluting stent platforms for the treatment of cardiovascular disease, today announced two key presentations scheduled for the 2010 EuroPCR meeting featuring the company's cardiovascular innovations.

20 May 2010

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.

20 May 2010

A.P. Pharma receives Nasdaq non-compliance notice

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).

20 May 2010

SBANE recognizes Isis Biopolymer with 2010 Rising Star Award

Isis Biopolymer has been awarded the 2010 Rising Star Award by SBANE (Smaller Business Association of New England). The Rising Star is a coveted annual award that honors innovative products and services offered by early-stage companies in New England.

19 May 2010

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent Office (USPTO) has issued a patent (US 7,704,985) entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases." The patent claims the use of beclomethasone dipropionate (BDP) to treat irritable bowel syndrome (IBS), a painful gastrointestinal condition that affects approximately 15% of the population in the industrialized world.

19 May 2010

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI).

19 May 2010

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Generex Biotechnology Corporation announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced positive interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 May 2010

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Vect-Horus is a biotechnology company based on the scientific work of Dr. Michel Khrestchatisky and specializes in the development of peptide and pseudo-peptide-based vector molecules for drug targeting and delivery to the central nervous system (CNS).

18 May 2010

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.

18 May 2010

Echo Therapeutics first-quarter net loss increases to $1.9 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced financial results for the period ended March 31, 2010.

18 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

Soligenix first-quarter revenues decrease to $336,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010.

17 May 2010

Drug Delivery News and Research

Further Reading

InspireMD announces next generation MGuard Prime net protective Cobalt Chromium stent system

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

Research findings on pediatric ILD published online in PED

PIONEER trial evaluates new safe concept of stent-drug combination

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Joint research by UB and CDC could lead to new generation of antiviral medicines

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

Elixir Medical announces presentations from EXCELLA II Clinical Trial at 2010 EuroPCR

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

A.P. Pharma receives Nasdaq non-compliance notice

SBANE recognizes Isis Biopolymer with 2010 Rising Star Award

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Echo Therapeutics first-quarter net loss increases to $1.9 million

Emisphere Technologies first-quarter net loss increases to $18.5 million

Soligenix first-quarter revenues decrease to $336,000

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News